Allurion Technologies (ALUR)
OTHER OTC:ALUR
Want to see ALUR full AI Analyst Report?
Top Page
Allurion Technologies
(OTC:ALUR)
Select Model
Select Model
Rating:43Neutral
Price Target:
$7.00
▲(775.00% Upside)
Action:Reiterated
Date:06/19/26
ALUR’s score is driven down primarily by very weak financial performance (shrinking revenue, very large losses, heavy cash burn, and negative equity that increases funding/dilution risk). Technicals also detract due to a clear downtrend and negative momentum. Valuation offers limited support because losses make the P/E less meaningful and there is no dividend yield.
Positive Factors
Distinct non-surgical product + platform
Allurion’s core device plus digital monitoring and clinical support creates a differentiated, integrated offering that supports provider adoption and program delivery. This business-model mix can drive scalable service bundles, recurring program revenue, and stickier customer relationships over the medium term.
Negative Factors
Multi-year revenue contraction
A steep, multi-year sales decline erodes scale, reduces network effects and weakens provider relationships. Sustained revenue shrinkage makes it harder to cover fixed costs, slows adoption of the platform, and lengthens the timeframe to restore sustainable growth absent clear new market traction.
Read all positive and negative factors
Positive Factors
Negative Factors
Distinct non-surgical product + platform
Allurion’s core device plus digital monitoring and clinical support creates a differentiated, integrated offering that supports provider adoption and program delivery. This business-model mix can drive scalable service bundles, recurring program revenue, and stickier customer relationships over the medium term.
Read all positive factors
Allurion Technologies (ALUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.48M
Dividend YieldN/A
Average Volume (3M)88.72K
Price to Earnings (P/E)―
Beta (1Y)2.40
Revenue Growth-55.49%
EPS Growth21.55%
CountryUS
Employees134
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-56.40
Shares Outstanding1,000,417
10 Day Avg. Volume45,410
30 Day Avg. Volume88,723
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-0.12
Price to Sales (P/S)0.61
P/FCF Ratio-0.32
Enterprise Value/Market Cap3.89
Enterprise Value/Revenue2.31
Enterprise Value/Gross Profit4.39
Enterprise Value/Ebitda-0.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-20.25
Revenue Forecast (FY)$13.70M
Allurion Technologies Business Overview & Revenue Model
Company Description
Allurion Technologies Inc. is dedicated to combating obesity by offering a comprehensive weight management ecosystem designed for individuals with excess weight. At the core of its solution is the Allurion Program, featuring the innovative Allurio...
How the Company Makes Money
Allurion primarily generates revenue from the commercialization of its weight-loss solution centered on the Allurion Balloon. Revenue is earned through the sale of the balloon and associated program components delivered to healthcare providers/cli...
Allurion Technologies Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 19, 2026
Earnings Call Sentiment Neutral
The call highlighted significant progress in the FDA approval process and successful restructuring efforts that improved financial efficiencies. However, these positives were tempered by a considerable decline in revenue and gross profit. The company's strategic initiatives, such as debt restructuring and R&D advancements, indicate a positive long-term outlook.Positive Updates
FDA Approval Process Milestones
Allurion passed several critical milestones towards FDA approval for the Allurion Smart Capsule, including the completion of the substantive review phase with no observations or Form 483 issued, indicating readiness for the U.S. market.
Negative Updates
Revenue Decline
Revenue for the third quarter of 2025 was $2.7 million, a significant decrease from $5.4 million for the same period in 2024, primarily due to restructuring.
Read all updates
Q3-2025 Updates
Positive
Negative
FDA Approval Process Milestones
Allurion passed several critical milestones towards FDA approval for the Allurion Smart Capsule, including the completion of the substantive review phase with no observations or Form 483 issued, indicating readiness for the U.S. market.
Read all positive updates
Company Guidance
In the third quarter earnings call, Allurion Technologies provided several updates and metrics regarding its financial performance and strategic initiatives. The company reported a revenue of $2.7 million, reflecting a restructuring to focus on accounts promoting metabolically healthy weight loss. Operating expenses decreased by 29% to $10.9 million, narrowing the operating loss to $9.6 million, a 22% improvement from the previous year. Adjusted operating expenses were $8.4 million, and adjusted net operating loss was $6.9 million, both showing significant improvements from the prior year. Allurion also highlighted its progress toward FDA approval for the Allurion Smart Capsule, passing critical milestones such as the pre-approval and BIMO inspections with no observations. Furthermore, the company announced plans to restructure its balance sheet, aiming to be debt-free, and has initiated a transaction to exchange outstanding debt for convertible preferred equity. The strategic pivot to focus on combination therapy with GLP-1s and the development of a drug-eluting balloon as part of its R&D pipeline were emphasized as key components of Allurion's future growth strategy.Allurion Technologies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.60M | 15.23M | 32.11M | 53.47M | 64.21M | 38.24M |
| Gross Profit | 6.64M | 9.57M | 21.50M | 41.50M | 50.73M | 29.19M |
| EBITDA | -38.94M | -27.70M | -22.17M | -69.03M | -32.28M | -8.01M |
| Net Income | -33.35M | -28.75M | -26.15M | -80.61M | -37.74M | -12.39M |
Balance Sheet | ||||||
| Total Assets | 13.99M | 15.77M | 32.81M | 71.71M | 51.37M | 39.35M |
| Cash, Cash Equivalents and Short-Term Investments | 5.06M | 5.41M | 15.38M | 38.04M | 7.68M | 25.84M |
| Total Debt | 29.45M | 29.04M | 37.92M | 41.86M | 59.53M | 26.14M |
| Total Liabilities | 91.91M | 92.96M | 110.79M | 142.20M | 83.68M | 73.64M |
| Stockholders Equity | -77.91M | -77.19M | -77.98M | -70.49M | -32.31M | -34.28M |
Cash Flow | ||||||
| Free Cash Flow | -22.70M | -28.95M | -42.91M | -65.59M | -48.53M | -15.24M |
| Operating Cash Flow | -22.70M | -28.95M | -42.30M | -63.98M | -46.98M | -14.33M |
| Investing Cash Flow | 0.00 | 0.00 | -611.00K | -1.61M | -1.55M | -912.00K |
| Financing Cash Flow | 7.34M | 18.97M | 20.21M | 95.99M | 30.54M | 28.95M |
Allurion Technologies Technical Analysis
Negative
0.80
Price Trends
11.44
Negative
12.59
Negative
19.52
Negative
Market Momentum
-0.83
Positive
35.57
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALUR, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 10.94, below the 50-day MA of 11.44, and below the 200-day MA of 19.52, indicating a bearish trend. The MACD of -0.83 indicates Positive momentum. The RSI at 35.57 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALUR.
Allurion Technologies Risk Analysis
Allurion Technologies disclosed 88 risk factors in its most recent earnings report. Allurion Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allurion Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $12.42M | -0.16 | -164.92% | ― | -9.46% | 18.03% | |
46 Neutral | $4.57M | -0.10 | -279.58% | ― | 129.04% | 74.30% | |
46 Neutral | $6.68M | >-0.01 | -57.19% | ― | ― | 27.91% | |
45 Neutral | $19.67M | -5.97 | -148.64% | ― | 7.73% | 55.39% | |
43 Neutral | $7.48M | -2.32 | 58.76% | ― | -55.49% | 21.55% | |
41 Neutral | $9.11M | -0.48 | -204.04% | ― | -59.95% | 56.67% |
* Healthcare Sector Average
ALUR
Allurion Technologies
7.48
-28.67
-79.31%
IRIX
Iridex
1.13
0.18
18.95%
SINT
Sintx Technologies
2.11
-0.96
-31.27%
CODX
Co-Diagnostics
3.37
-4.29
-55.98%
XAIR
Beyond Air
0.36
-3.43
-90.51%
NVNO
enVVeno Medical
10.00
-132.80
-93.00%
Allurion Technologies Corporate Events
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Allurion Technologies Executes Reverse Stock Split to Regain Listing
Neutral
Jun 17, 2026
Allurion Technologies, Inc., a metabolically focused weight-loss medtech company, said that shareholders approved a reverse stock split at the 2025 annual meeting held on Dec. 18, 2025. The board later set the ratio at 1-for-15, reducing the compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.